F-star Therapeutics Profit Margin

F-star Therapeutics (FSTX) currently reports a profit margin of -212.48% as of September 2022. That compares with -1170.87% in the prior-year period — up 81.9% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore F-star Therapeutics's profit margin history and peer comparisons.

F-star Therapeutics's profit margin increased from -1170.87% to -212.48% — a 81.9% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

F-star Therapeutics's profit margin of -212.48% is lower than the Healthcare sector average of 13.89%. That is roughly 1629.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but F-star Therapeutics's current -212.48% should be judged against Healthcare norms (sector average: 13.89%) and against FSTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -212.48%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for F-star Therapeutics, and consider following FSTX for alerts when major investors trade the stock.